References
- Treating for two: data and statistics (2017). www.cdc.gov/pregnancy/meds/treatingfortwo/index.html.
- Mitchell AA Gilboa SM Werler MM Kelley KE Louik C Hernández-Díaz S . Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am. J. Obstet. Gynecol.205 (1), 51.e51–51.e58 (2011).
- Pernia S Demaagd G . The new pregnancy and lactation labeling rule. P T.41 (11), 713–715 (2016).
- Griffiths SK Campbell JP . Placental structure, function and drug transfer. Cont. Educ. Anaesth. Crit. Care Pain15 (2), 84–89 (2015).
- Burkey BW Holmes AP . Evaluating medication use in pregnancy and lactation: what every pharmacist should know. J. Pediatr. Pharmacol. Ther.18 (3), 247–258 (2013).
- Lobo I Zhaurova K . Birth defects: causes and statistics. Nat. Educ.1 (1), 18 (2008).
- Harris LK . Could peptide-decorated nanoparticles provide an improved approach for treating pregnancy complications?Nanomedicine (Lond.)11 (17), 2235–2238 (2016).
- Muoth C Aengenheister L Kucki M Wick P Buerki-Thurnherr T . Nanoparticle transport across the placental barrier: pushing the field forward. Nanomedicine (Lond.)11 (8), 941–957 (2016).
- Keelan JA . Nanotoxicology: nanoparticles versus the placenta. Nat. Nanotechnol.6 (5), 263–264 (2011).
- Kaul G Clemons TI Iyer Ks Pugazhenthi K Keelan J . Mechanism of uptake of cationic nanoparticles by human placental syncytiotrophoblasts. Reproductive Sci.20 (3 Suppl.), A113 (2013).
- Keelan JA Leong JW Ho D Iyer KS . Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy. Nanomedicine (Lond).10 (14), 2229–2247 (2015).
- Mori C Nakamura N Todaka E et al. Correlation between human maternal–fetal placental transfer and molecular weight of PCB and dioxin congeners/isomers. Chemosphere114, 262–267 (2014).
- Faber JJ Thornburg KL Binder ND . Physiology of placental transfer in mammals. Am. Zoologist32 (2), 343–354 (1992).
- Andaluz A Santos L Garcia F Ferrer RI Fresno L Moll X . Maternal and foetal cardiovascular effects of the anaesthetic alfaxalone in 2-Hydroxypropyl-cyclodextrin in the pregnant ewe. ScientificWorldJournal2013, 6 (2013).
- Menjoge AR Rinderknecht AL Navath RS et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J. Control. Rel.150 (3), 326–338 (2011).
- Barzago MM Bortolotti A Stellari FF et al. Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion. J. Pharmacol. Exp. Ther.277 (1), 79–86 (1996).
- Tuzel-Kox SN Patel HM Kox WJ . Uptake of drug-carrier liposomes by placenta: transplacental delivery of drugs and nutrients. J. Pharmacol. Exp. Ther.274 (1), 104–109 (1995).
- Refuerzo JS Alexander JF Leonard F Leon M Longo M Godin B . Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model. Am. J. Obstet. Gynecol.212 (4), (2015).
- Yang H Du L Tian X et al. Effects of nanoparticle size and gestational age on maternal biodistribution and toxicity of gold nanoparticles in pregnant mice. Toxicol Lett.230 (1), 10–18 (2014).
- Balansky R Longobardi M Ganchev G et al. Transplacental clastogenic and epigenetic effects of gold nanoparticles in mice. Mutat Res.751–752 (1), 42–48 (2013).
- Campagnolo L Massimiani M Palmieri G et al. Biodistribution and toxicity of pegylated single wall carbon nanotubes in pregnant mice. Part Fibre Toxicol.10, 21 (2013).
- Philbrook NA Walker VK Afrooz AR Saleh NB Winn LM . Investigating the effects of functionalized carbon nanotubes on reproduction and development in Drosophila melanogaster and CD-1 mice. Reprod. Toxicol.32 (4), 442–448 (2011).
- Huang X Zhang F Sun X et al. The genotype-dependent influence of functionalized multiwalled carbon nanotubes on fetal development. Biomaterials35 (2), 856–865 (2014).
- Pietroiusti A Massimiani M Fenoglio I et al. Low doses of pristine and oxidized single-wall carbon nanotubes affect mammalian embryonic development. ACS Nano.5 (6), 4624–4633 (2011).